Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO) assisting biopharma companies with services spanning across the development life cycle, will nearly triple the size of its Swedish facility as part of its €35 million ($34.7 million) investment across its European operations.   The firm is investing in drug substance manufacture in Södertälje to increase its capacity and includes a new production line and a larger preparative High Performance Liquid Chromatog...